This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Perkins, W. J. Articles by Michenfelder, J. D. Search for Related Content PubMed PubMed Citation Articles by Perkins, W. J. Articles by Michenfelder, J. D.

Stroke, Vol 22, 902-909, Copyright © 1991 by American Heart Association

ARTICLES

Pretreatment with U74006F improves neurologic outcome following complete cerebral ischemia in dogs

WJ Perkins, LN Milde, JH Milde and JD Michenfelder
Department of Anesthesiology, Mayo Clinic, Rochester, Minn. 55905.

We examined the 21-aminosteroid U74006F, a potent inhibitor of lipid peroxidation, for potential neuroprotective effects in a canine model of complete cerebral ischemia. Two 1.5-mg/kg boluses were administered to six dogs, the first bolus 15 minutes prior to a 12-minute episode of complete cerebral ischemia and the second bolus after 11 minutes of ischemia, 1 minute prior to reperfusion. Using this dosage regimen, plasma U74006F levels of greater than 0.3 microgram/ml were maintained for up to an hour postischemia. An additional six animals received equal volumes of the citrate vehicle solution. At 24 and 48 hours postischemia, the dogs were neurologically evaluated by an observer blinded as to treatment selection. All six U74006F-treated animals had a normal neurologic outcome at 48 hours postischemia, while the citrate vehicle-treated animals all suffered moderate to severe neurologic deficits. The difference in outcome was significant at both 24 and 48 hours (p less than 0.005). Although U74006F is a 21-aminosteroid, it is not reported to possess glucocorticoid activity. This is supported by the present finding that no changes in plasma glucose concentration were observed following administration of the drug. The systemic vitamin E levels of citrate vehicle-treated animals decreased significantly (from 4.10 +/- 0.46 micrograms/ml to 2.95 +/- 0.38 micrograms/ml, p less than 0.05), whereas the vitamin E levels in U74006F-treated animals did not decrease significantly. These results suggest that U74006F may be of benefit in improving neurologic outcome when administered prior to an episode of complete cerebral ischemia.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				R. F. Villa and A. Gorini Pharmacology of Lazaroids and Brain Energy Metabolism: A Review Pharmacol. Rev., March 1, 1997; 49(1): 99 - 136. [Abstract] [Full Text] [PDF]

				H. Kim, R. C. Koehler, P. D. Hurn, E. D. Hall, and R. J. Traystman Amelioration of Impaired Cerebral Metabolism After Severe Acidotic Ischemia by Tirilazad Posttreatment in Dogs Stroke, January 1, 1996; 27(1): 114 - 121. [Abstract] [Full Text]

				M. D. Ginsberg Review : Neuroprotection in Brain Ischemia: An Update (Part II Neuroscientist, May 1, 1995; 1(3): 164 - 175. [Abstract] [PDF]